MN 553 FINAL EXAM 2025-2026 ACTUAL EXAM 2
LATEST 100 QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES (100% VERIFIED
ANSWERS)
A |potentially |life-threatening |adverse |response |to |angiotensin-converting |enzyme |inhibitors |is
|angioedema. |Which |of |the |following |statements |is |true |about |this |adverse |response? |Question
|options:
A. Swelling |of |the |tongue |or |hoarseness |are |the |most |common |symptoms.
B. It |appears |to |be |related |to |the |decrease |in |aldosterone |production.
C. Presence |of |a |dry, |hacky |cough |indicates |a |high |risk |for |this |adverse |response.
D. Because |it |takes |time |to |build |up |a |blood |level, |it |occurs |after |being |on |the |drug |for |about |1
|week. |- |ANSWER-A. |Swelling |of |the |tongue |or |hoarseness |are |the |most |common |symptoms.
Jamison |has |been |prescribed |citalopram |(Celexa) |to |treat |his |depression. |Education |regarding |how
|quickly |selective |serotonin |reuptake |inhibitor |(SSRI) |antidepressants |work |would |be: |Question
|options:
A. Appetite |and |concentration |improve |in |the |first |1 |to |2 |weeks.
B. Sleep |should |improve |almost |immediately |upon |starting |citalopram.
C. Full |response |to |the |SSRI |may |take |2 |to |4 |months |after |he |reaches |the |full |therapeutic |dose.
D. His |dysphoric |mood |will |improve |in |1 |to |2 |weeks. |- |ANSWER-A. |Appetite |and |concentration |improve
|in |the |first |1 |to |2 |weeks.
Larry |is |taking |allopurinol |to |prevent |gout. |Monitoring |of |a |patient |who |is |taking |allopurinol
|includes:Question |options:
A. Complete |blood |count
B. Blood |glucose
C. C-reactive |protein
D. BUN, |creatinine, |and |creatinine |clearance |- |ANSWER-D. |BUN, |creatinine, |and |creatinine |clearance
When |a |pharmacoeconomic |analysis |looks |at |two |or |more |treatment |alternatives |that |are |considered
|equal |in |efficacy |and |compares |the |costs |of |each |it |is |referred |to |as: |Question |options:
A. Cost-minimization | analysis
B. Cost-of-illness | analysis
,C. Cost-effectiveness | analysis
D. Cost-benefit |analysis |- |ANSWER-A. |Cost-minimization |analysis
Being |competent |in |the |use |of |information |technology |in |clinical |practice |is |expected |in |professional
|nurses. |Advanced |practice |competence |includes |the |ability |to: |Question |options:
A. Search |for |information |using |the |most |common |search |engines
B. Serve |as |content |experts |in |developing, |implementing, |and |evaluating |information
C. Systems |Write |programs |to |assure |the |integrity |of |health |information
D. Use |information |technology |to |prescribe |drugs |- |ANSWER-B. |Serve |as |content |experts |in
|developing, |implementing, |and |evaluating |information
Instructions |for |the |use |of |nicotine |gum |include: |Question |options:
A. Chew |the |gum |quickly |to |get |a |peak |effect.
B. The |gum |should |be |"parked" |in |the |buccal |space |between |chewing.
C. Acidic |drinks |such |as |coffee |help |with |the |absorption |of |the |nicotine.
D. The |highest |abstinence |rates |occur |if |the |patient |chews |the |gum |when |he |or |she |is |having
|cravings. |- |ANSWER-B. |The |gum |should |be |"parked" |in |the |buccal |space |between |chewing.
A |laboratory |result |indicates |that |the |peak |level |for |a |drug |is |above |the |minimum |toxic
|concentration. |This |means |that |the:
Question |options:
A. Concentration |will |produce |therapeutic |effects
B. Concentration |will |produce |an |adverse |response
C. Time |between |doses |must |be |shortened
D. Duration |of |action |of |the |drug |is |too |long |- |ANSWER-B. |Concentration |will |produce |an
|adverse |response
An |acceptable |first-line |treatment |for |peptic |ulcer |disease |with |positive |H. |pylori |test |is: |Question
|options:
A. Histamine2 |receptor |antagonists |for |4 |to |8 |weeks
B. Proton |pump |inhibitor |bid |for |12 |weeks |until |healing |is |complete
,C. Proton |pump |inhibitor |bid |plus |clarithromycin |plus |amoxicillin |for |14 |days
D. Proton |pump |inhibitor |bid |and |levofloxacin |for |14 |days |- |ANSWER-C. |Proton |pump |inhibitor |bid
|plus |clarithromycin |plus |amoxicillin |for |14 |days
Alterations |in |drug |metabolism |among |Asians |may |lead |to: |Question |options:
A. Slower |metabolism |of |antidepressants, |requiring |lower |doses
B. Faster |metabolism |of |neuroleptics, |requiring |higher |doses
C. Altered |metabolism |of |omeprazole, |requiring |higher |doses
D. Slower |metabolism |of |alcohol, |requiring |higher |doses |- |ANSWER-A. |Slower |metabolism
|of |antidepressants, |requiring |lower |doses
Patients |who |are |prescribed |exogenous |androgens |need |to |be |warned |that |decreased |libido:
|Question |options:
A. Is |an |unusual |side |effect |of |androgens |and |should |be |reported |to |the |provider
B. Is |treated |with |increased |doses |of |androgens, |so |the |patient |should |let |the |provider |know |if
|he |is |having |problems
C. May |be |a |sign |of |early |prostate |cancer |and |he |should |make |an |appointment |for |a |prostate
|screening |exam
D. May |occur |with |androgen |therapy |- |ANSWER-D. |May |occur |with |androgen |therapy
A |woman |who |is |pregnant |and |has |hyperthyroidism |is |best |managed |by |a |specialty |team |who |will
|most |likely |treat |her |with: |Question |options:
A. Methimazole
B. Propylthiouracil |(PTU)
C. Radioactive |iodine
D. Nothing, |treatment |is |best |delayed |until |after |her |pregnancy |ends |- |ANSWER-B. |Propylthiouracil |(PTU)
The |dosage |of |Vitamin |B12 |to |initially |treat |pernicious |anemia |is: |Question |options:
A. Nasal |cyanocobalamin |1 |gram |spray |in |each |nostril |daily |x |1 |week |then |weekly |x |1 |month
B. Vitamin |B12 |IM |monthly
C. Vitamin |B12 |1,000 |mcg |IM |daily |x |1 |week |then |1,000 |mg |IM |weekly |for |a |month
, D. Oral |cobalamin |1,000 |mcg |daily |- |ANSWER-C. |Vitamin |B12 |1,000 |mcg |IM |daily |x |1 |week |then |1,000
|mg |IM |weekly |for |a |month
A |provider |may |consider |testing |for |CYP2D6 |variants |prior |to |starting |tamoxifen |for |breast |cancer
|to:Question |options:
A. Ensure |the |patient |will |not |have |increased |adverse |drug |reactions |to |the |tamoxifen
B. Identify |potential |drug-drug |interactions |that |may |occur |with |tamoxifen
C. Reduce |the |likelihood |of |therapeutic |failure |with |tamoxifen |treatment
D. Identify |poor |metabolizers |of |tamoxifen |- |ANSWER-C. |Reduce |the |likelihood |of |therapeutic
|failure |with |tamoxifen |treatment
First-line |therapy |for |treating |topical |fungal |infections |such |as |tinea |corporis |(ringworm) |or |tinea |pedis
|(athlete's |foot) |would |be: |Question |options:
A. OTC |topical |azole |(clotrimazole, |miconazole)
B. Oral |terbinafine
C. Oral |griseofulvin |microsize
D. Nystatin |cream |or |ointment |- |ANSWER-A. |OTC |topical |azole |(clotrimazole, |miconazole)
Goals |when |treating |tuberculosis |include: |Question |options:
A. Completion |of |recommended |therapy
LATEST 100 QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES (100% VERIFIED
ANSWERS)
A |potentially |life-threatening |adverse |response |to |angiotensin-converting |enzyme |inhibitors |is
|angioedema. |Which |of |the |following |statements |is |true |about |this |adverse |response? |Question
|options:
A. Swelling |of |the |tongue |or |hoarseness |are |the |most |common |symptoms.
B. It |appears |to |be |related |to |the |decrease |in |aldosterone |production.
C. Presence |of |a |dry, |hacky |cough |indicates |a |high |risk |for |this |adverse |response.
D. Because |it |takes |time |to |build |up |a |blood |level, |it |occurs |after |being |on |the |drug |for |about |1
|week. |- |ANSWER-A. |Swelling |of |the |tongue |or |hoarseness |are |the |most |common |symptoms.
Jamison |has |been |prescribed |citalopram |(Celexa) |to |treat |his |depression. |Education |regarding |how
|quickly |selective |serotonin |reuptake |inhibitor |(SSRI) |antidepressants |work |would |be: |Question
|options:
A. Appetite |and |concentration |improve |in |the |first |1 |to |2 |weeks.
B. Sleep |should |improve |almost |immediately |upon |starting |citalopram.
C. Full |response |to |the |SSRI |may |take |2 |to |4 |months |after |he |reaches |the |full |therapeutic |dose.
D. His |dysphoric |mood |will |improve |in |1 |to |2 |weeks. |- |ANSWER-A. |Appetite |and |concentration |improve
|in |the |first |1 |to |2 |weeks.
Larry |is |taking |allopurinol |to |prevent |gout. |Monitoring |of |a |patient |who |is |taking |allopurinol
|includes:Question |options:
A. Complete |blood |count
B. Blood |glucose
C. C-reactive |protein
D. BUN, |creatinine, |and |creatinine |clearance |- |ANSWER-D. |BUN, |creatinine, |and |creatinine |clearance
When |a |pharmacoeconomic |analysis |looks |at |two |or |more |treatment |alternatives |that |are |considered
|equal |in |efficacy |and |compares |the |costs |of |each |it |is |referred |to |as: |Question |options:
A. Cost-minimization | analysis
B. Cost-of-illness | analysis
,C. Cost-effectiveness | analysis
D. Cost-benefit |analysis |- |ANSWER-A. |Cost-minimization |analysis
Being |competent |in |the |use |of |information |technology |in |clinical |practice |is |expected |in |professional
|nurses. |Advanced |practice |competence |includes |the |ability |to: |Question |options:
A. Search |for |information |using |the |most |common |search |engines
B. Serve |as |content |experts |in |developing, |implementing, |and |evaluating |information
C. Systems |Write |programs |to |assure |the |integrity |of |health |information
D. Use |information |technology |to |prescribe |drugs |- |ANSWER-B. |Serve |as |content |experts |in
|developing, |implementing, |and |evaluating |information
Instructions |for |the |use |of |nicotine |gum |include: |Question |options:
A. Chew |the |gum |quickly |to |get |a |peak |effect.
B. The |gum |should |be |"parked" |in |the |buccal |space |between |chewing.
C. Acidic |drinks |such |as |coffee |help |with |the |absorption |of |the |nicotine.
D. The |highest |abstinence |rates |occur |if |the |patient |chews |the |gum |when |he |or |she |is |having
|cravings. |- |ANSWER-B. |The |gum |should |be |"parked" |in |the |buccal |space |between |chewing.
A |laboratory |result |indicates |that |the |peak |level |for |a |drug |is |above |the |minimum |toxic
|concentration. |This |means |that |the:
Question |options:
A. Concentration |will |produce |therapeutic |effects
B. Concentration |will |produce |an |adverse |response
C. Time |between |doses |must |be |shortened
D. Duration |of |action |of |the |drug |is |too |long |- |ANSWER-B. |Concentration |will |produce |an
|adverse |response
An |acceptable |first-line |treatment |for |peptic |ulcer |disease |with |positive |H. |pylori |test |is: |Question
|options:
A. Histamine2 |receptor |antagonists |for |4 |to |8 |weeks
B. Proton |pump |inhibitor |bid |for |12 |weeks |until |healing |is |complete
,C. Proton |pump |inhibitor |bid |plus |clarithromycin |plus |amoxicillin |for |14 |days
D. Proton |pump |inhibitor |bid |and |levofloxacin |for |14 |days |- |ANSWER-C. |Proton |pump |inhibitor |bid
|plus |clarithromycin |plus |amoxicillin |for |14 |days
Alterations |in |drug |metabolism |among |Asians |may |lead |to: |Question |options:
A. Slower |metabolism |of |antidepressants, |requiring |lower |doses
B. Faster |metabolism |of |neuroleptics, |requiring |higher |doses
C. Altered |metabolism |of |omeprazole, |requiring |higher |doses
D. Slower |metabolism |of |alcohol, |requiring |higher |doses |- |ANSWER-A. |Slower |metabolism
|of |antidepressants, |requiring |lower |doses
Patients |who |are |prescribed |exogenous |androgens |need |to |be |warned |that |decreased |libido:
|Question |options:
A. Is |an |unusual |side |effect |of |androgens |and |should |be |reported |to |the |provider
B. Is |treated |with |increased |doses |of |androgens, |so |the |patient |should |let |the |provider |know |if
|he |is |having |problems
C. May |be |a |sign |of |early |prostate |cancer |and |he |should |make |an |appointment |for |a |prostate
|screening |exam
D. May |occur |with |androgen |therapy |- |ANSWER-D. |May |occur |with |androgen |therapy
A |woman |who |is |pregnant |and |has |hyperthyroidism |is |best |managed |by |a |specialty |team |who |will
|most |likely |treat |her |with: |Question |options:
A. Methimazole
B. Propylthiouracil |(PTU)
C. Radioactive |iodine
D. Nothing, |treatment |is |best |delayed |until |after |her |pregnancy |ends |- |ANSWER-B. |Propylthiouracil |(PTU)
The |dosage |of |Vitamin |B12 |to |initially |treat |pernicious |anemia |is: |Question |options:
A. Nasal |cyanocobalamin |1 |gram |spray |in |each |nostril |daily |x |1 |week |then |weekly |x |1 |month
B. Vitamin |B12 |IM |monthly
C. Vitamin |B12 |1,000 |mcg |IM |daily |x |1 |week |then |1,000 |mg |IM |weekly |for |a |month
, D. Oral |cobalamin |1,000 |mcg |daily |- |ANSWER-C. |Vitamin |B12 |1,000 |mcg |IM |daily |x |1 |week |then |1,000
|mg |IM |weekly |for |a |month
A |provider |may |consider |testing |for |CYP2D6 |variants |prior |to |starting |tamoxifen |for |breast |cancer
|to:Question |options:
A. Ensure |the |patient |will |not |have |increased |adverse |drug |reactions |to |the |tamoxifen
B. Identify |potential |drug-drug |interactions |that |may |occur |with |tamoxifen
C. Reduce |the |likelihood |of |therapeutic |failure |with |tamoxifen |treatment
D. Identify |poor |metabolizers |of |tamoxifen |- |ANSWER-C. |Reduce |the |likelihood |of |therapeutic
|failure |with |tamoxifen |treatment
First-line |therapy |for |treating |topical |fungal |infections |such |as |tinea |corporis |(ringworm) |or |tinea |pedis
|(athlete's |foot) |would |be: |Question |options:
A. OTC |topical |azole |(clotrimazole, |miconazole)
B. Oral |terbinafine
C. Oral |griseofulvin |microsize
D. Nystatin |cream |or |ointment |- |ANSWER-A. |OTC |topical |azole |(clotrimazole, |miconazole)
Goals |when |treating |tuberculosis |include: |Question |options:
A. Completion |of |recommended |therapy
